Seminar Series | Boston/Cambridge
Strands of Innovation: The Future of Genomic Medicine
Seminar Series | Boston/Cambridge
Strands of Innovation: The Future of Genomic Medicine
Seminar series highlights | Boston/Cambridge
When
November 12, 2025
1:00 p.m. - Registration
2:00 p.m. - Speaker series
5:00 p.m. - Happy Hour and Appetizers
Where
Glass House
Fee: No Cost.
Limited Seats.
Register below.
Agenda
De-Risking Genome Editing: Off-Target Assessment Strategies for IND Success
Stephano Spano Mellon, PhD
Global Study Manager
MaxCyte
Stephano Spano Mello, Ph.D. is a genetics and genomics specialist and Global Study Manager at MaxCyte/Sequre services. With a background in cancer research, he now leads off-target assessment efforts to ensure safer, more precise cell and gene therapies ready for regulatory approval.
MaxCyte Electroporation: Enabling Gene Editing and Cell Therapy
Nitin Kulkarni, PhD
Senior Field Application Scientist
MaxCyte
Nitin Kulkarni is a Sr. Field Application Scientist at MaxCyte for last 5 years. Nitin has worked on all the stages of cell and gene therapy application on MaxCyte’s platform ranging from optimizing experiments in academic settings, process development for clinical application to all the way assisting commercial manufacturing for cell therapies. For over 12 years, he has helped advance customer applications and technologies with his expertise in cell culture, molecular biology, immunology, bioprocessing and microfluidic cell isolation technologies.
Creating an mRNA Manufacturing Platform for Hands-on Training
Baley Reeves, PhD
Director
National Center for Therapeutics Manufacturing Texas A&M Engineering
Baley Reeves, PhD is the Director of the National Center for Therapeutics Manufacturing. She has over 18 years of experience in downstream processing and over 14 years of experience in biomanufacturing workforce training, and has expertise in the recovery and purification of recombinant proteins, vaccines, and gene therapy products, as well as experience in cGMP manufacturing and process development. Prior to joining NCTM, Baley was a senior scientist at the Biomanufacturing Training and Education Center (BTEC), where she developed and taught courses for biotech industry leaders, regulatory agencies, and the WHO.
Innovative Design Strategies, Modifications, and Methods to Improve RNA Therapeutics for the Future
Daniel Dixon, PhD
Senior Application Scientist, Technical Design
TriLink BioTechnologies
Daniel Dixon, PhD is a Senior Application Scientist at TriLink Biotechnologies with expertise in in vitro transcription, entomology, and molecular biology. Previously, he was a Field Applications Scientist for Thermo Fisher Scientific, supporting our Nucleic Acid and Advanced Therapeutics Group. Prior to working in Nucleic Acid Therapeutics, he also worked at Thermo Fisher Scientific in the Viral Vector Services division as a Lead Scientist in Upstream Process Development, scaling up client processes from small to manufacturing scale.
Questions?
Email us at marketing@trilinkbiotech.com
TriLink BioTechnologies does not sell or distribute your information to third parties. For more information, please refer to our Privacy Policy
